Statement of Changes in Beneficial Ownership (4)
April 13 2020 - 6:38PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
EHRLICH JASON |
2. Issuer Name and Ticker or Trading Symbol
Kodiak Sciences Inc.
[
KOD
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
See Remarks |
|
(Last)
(First)
(Middle)
2631 HANOVER STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/9/2020 |
|
(Street)
PALO ALTO, CA 94304
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 4/9/2020 | | M | | 15000 | A | (1) | 37542 | D | |
| Common Stock | 4/9/2020 | | F | | 4058 (2) | D | $50.67 | 33484 | D | |
| Common Stock | 4/9/2020 | | S | | 938 (3) | D | $47.5394 (4) | 32546 | D | |
| Common Stock | 4/9/2020 | | S | | 345 (3) | D | $48.7046 (5) | 32201 | D | |
| Common Stock | 4/9/2020 | | S | | 917 (3) | D | $49.5478 (6) | 31284 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Restricted Stock Units | (1) | 4/9/2020 | | M | | | 15000 | (7) | (7) | Common Stock | 15000 | $0.00 | 15000 | D | |
| Explanation of Responses: |
| (1) | Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock. |
| (2) | Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting and settlement of 25% of the Reporting Person's restricted stock units granted on October 9, 2018. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). |
| (3) | These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. These sales were made to cover tax withholding obligations in connection with vesting and settlement of 25% of the Reporting Person's RSU granted on October 9, 2018. |
| (4) | The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $47.095 to $48.045, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. |
| (5) | The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $48.185 to $49.00, inclusive. |
| (6) | The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $49.29 to $49.83, inclusive. |
| (7) | 50% of the RSU vested 12 months after October 9, 2018 (the "Grant Date"), 25% of the RSU vested 18 months after the Grant Date and 25% of the RSU vest 24 months after the Grant Date. |
Remarks:
Chief Medical Officer and Chief Development Officer |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
EHRLICH JASON
2631 HANOVER STREET
PALO ALTO, CA 94304 |
|
| See Remarks |
|
Signatures
|
| /s/ Carlton Fleming, Attorney-in-Fact for Jason Ehrlich | | 4/13/2020 |
| **Signature of Reporting Person | Date |
Kodiak Sciences (NASDAQ:KOD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kodiak Sciences (NASDAQ:KOD)
Historical Stock Chart
From Apr 2023 to Apr 2024
